Dataset from A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00005905
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
创建时间：
2024-11-26
